Multi-center study of stem cell treatment of congenital heart disease

Recently, Mott Children's Hospital of the University of Michigan Health Center announced the launch of stem cell therapy for infants with single-ventricular heart disease

This multicenter randomized trial was jointly conducted by four clinical hospitals, including Mott Children's Hospital, and led by the University of Miami and Lurie Children's Hospital in Chicago

These stem cells were extracted during the first heart surgery after the child was born

Complex congenital heart disease: an intractable disease

Left heart dysplasia syndrome is one of the most complex forms of congenital heart disease, occurring in approximately 9% of children with congenital heart defects

At this time, for these children, the only feasible method is a heart transplant

Stem cells: a new hope for the treatment of complex congenital diseases

Stem cells are thought to release healing proteins, which stimulate the heart to repair defective myocardium, prevent deterioration of heart function, and strengthen the normal working right ventricle during heart development

Dr.

Complex congenital heart disease is currently difficult to treat, and traditional surgical treatment is not effective

At present, the above-mentioned Mott Children's Hospital and other hospitals have successively carried out clinical trials of stem cells in the treatment of complex congenital heart diseases to evaluate their safety and effectiveness

In fact, stem cells have been extensively studied in the field of cardiovascular diseases

refer to:

[1] https://labblog.

[2] Goldberg CS, Hu C, Brosig C, Gaynor JW, Mahle WT, Miller T, Mussatto KA, Sananes R, Uzark K, Trachtenberg F, Pizarro C, Pemberton VL, Lewis AB, Li JS, Jacobs JP, Cnota J , Atz AM, Lai WW, Bellinger D, Newburger JW; PHN INVESTIGATORS.

https://pubmed.

(Source: Internet, for reference only)